Astellas Pharma China, Inc.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Subsidiary
- Established
- 1994-10-14
- Employees
- -
- Market Cap
- -
- Website
- https://www.astellas.com.cn
A Study to Evaluate the Safety and Efficacy of a Modigraf® Based Immunosuppression Regimen in De Novo Pediatric Allograft Liver and Kidney Transplantation Recipients
Phase 4
Completed
- Conditions
- Liver TransplantationKidney Transplantation
- Interventions
- First Posted Date
- 2021-12-10
- Last Posted Date
- 2025-03-17
- Lead Sponsor
- Astellas Pharma China, Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT05153915
- Locations
- 🇨🇳
Site CN86003, Beijing, China
🇨🇳Site CN86006, Changsha, China
🇨🇳Site CN86001, Guangzhou, China
A Study of Modigraf® (Tacrolimus Granules) to Evaluate the Pharmacokinetics and Long-term Safety and Efficacy in De Novo Pediatric Allograft Liver and Kidney Transplantation Recipients
Phase 4
Completed
- Conditions
- Kidney TransplantationLiver Transplantation
- Interventions
- First Posted Date
- 2021-12-10
- Last Posted Date
- 2025-03-17
- Lead Sponsor
- Astellas Pharma China, Inc.
- Target Recruit Count
- 55
- Registration Number
- NCT05152628
- Locations
- 🇨🇳
Site CN86003, Beijing, China
🇨🇳Site CN86002, Guangzhou, China
🇨🇳Site CN86001, Shanghai, China
A Study to Evaluate Enfortumab Vedotin (ASG-22CE) in Chinese Participants With Locally Advanced or Metastatic Urothelial Cancer Who Previously Received Platinum-containing Chemotherapy and Programmed Cell Death Protein-1 ( PD 1) / (Programmed Death Ligand-1 (PD-L1) Inhibitor Therapy
Phase 2
Active, not recruiting
- Conditions
- Metastatic Urothelial Cancer
- Interventions
- Drug: Enfortumab vedotin
- First Posted Date
- 2021-08-09
- Last Posted Date
- 2025-04-13
- Lead Sponsor
- Astellas Pharma China, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT04995419
- Locations
- 🇨🇳
Site CN86001, Beijing, China
🇨🇳Site CN86009, Changsha, China
🇨🇳Site CN86002, Guangzhou, China
A Study to Evaluate the Pharmacokinetics and Safety of Fezolinetant in Healthy Chinese Female Subjects
- First Posted Date
- 2021-03-11
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Astellas Pharma China, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT04793204
- Locations
- 🇨🇳
Site CN86001, Bei'jing, China
A Study With Mirabegron 50 mg and 25 mg in Chinese Participants With Overactive Bladder
- First Posted Date
- 2020-09-24
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Astellas Pharma China, Inc.
- Target Recruit Count
- 249
- Registration Number
- NCT04562090
- Locations
- 🇨🇳
Site CN86020, Wuhan, Hubei, China
🇨🇳Site CN86001, Beijing, China
🇨🇳Site CN86004, Beijing, China
A Study to Investigate the Effect of Food With Mirabegron in Healthy Chinese Participants
Phase 4
Completed
- Conditions
- Pharmacokinetics of MirabegronHealthy Chinese SubjectsFood Effect
- Interventions
- First Posted Date
- 2020-08-06
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Astellas Pharma China, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT04501640
- Locations
- 🇨🇳
Site CN86001, Shanghai, China
A Study to Assess the Safety and Tolerability of Fezolinetant in Women Seeking Treatment for Relief of Vasomotor Symptoms (VMS) Associated With Menopause
- First Posted Date
- 2020-06-30
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Astellas Pharma China, Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT04451226
- Locations
- 🇨🇳
Site CN86002, Beijing, China
🇨🇳Site CN86015, Beijing, China
🇨🇳Site CN86029, Beijing, China
A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women in Asia Going Through Menopause
- First Posted Date
- 2020-01-21
- Last Posted Date
- 2025-01-31
- Lead Sponsor
- Astellas Pharma China, Inc.
- Target Recruit Count
- 302
- Registration Number
- NCT04234204
- Locations
- 🇨🇳
Site CN86001, Beijing, China
🇨🇳Site CN86002, Beijing, China
🇨🇳Site CN86017, Beijing, China
A Study to Evaluate the Pharmacokinetics and Safety of ASP015K in Healthy Chinese Subjects
- First Posted Date
- 2019-10-29
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Astellas Pharma China, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT04143477
- Locations
- 🇨🇳
Site CN86001, Beijing, China
A Pharmacokinetic Study of Zolbetuximab (IMAB362) in Chinese Subjects With Locally Advanced Unresectable or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma
Phase 1
Completed
- Conditions
- Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma
- Interventions
- First Posted Date
- 2019-09-12
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Astellas Pharma China, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT04086758
- Locations
- 🇨🇳
Site CN86001, Guangzhou, China